General Announcement::GPL receives ANDA tentative approval for Dapagliflozin Tablets

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
23-Mar-2020 12:23:01
Status
New
Announcement Sub Title
GPL receives ANDA tentative approval for Dapagliflozin Tablets
Announcement Reference
SG200323OTHRQL9L
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
23/03/2020 17:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin Tablets,5 mg and 10 mg

Attachments

SGX_PR_23032020.pdf
Total size =763K